1. Choi JY, Kim H, Jung YI, et al. Factors associated with anticholinergic burden among older patients in long-term care hospitals in Korea. Korean J Intern Med 2022;37:468–477.

2. Lee DH, Lee JH, Kim SY, et al. Optimal blood pressure target in the elderly: rationale and design of the HOW to Optimize eLDerly systolic Blood Pressure (HOWOLD-BP) trial. Korean J Intern Med 2022;37:1070–1081.

3. Kang SC, Koh HB, Kim HW, et al. Associations among Alzheimer disease, depressive disorder, and risk of end-stage kidney disease in elderly people. Kidney Res Clin Pract 2022;41:753–763.

4. Hong YA, Ban TH, Kang CY, et al. Trends in epidemiologic characteristics of end-stage renal disease from 2019 Korean Renal Data System (KORDS). Kidney Res Clin Pract 2021;40:52–61.

5. Gill J, Bunnapradist S, Danovitch GM, Gjertson D, Gill JS, Cecka M. Outcomes of kidney transplantation from older living donors to older recipients. Am J Kidney Dis 2008;52:541–552.

6. Hong YA. Are older adults safe and suitable candidate donors or recipients for kidney transplantation? Kidney Res Clin Pract 2022;41:271–274.

7. Lewis ED, Wu D, Meydani SN. Age-associated alterations in immune function and inflammation. Prog Neuropsychopharmacol Biol Psychiatry 2022;118:110576.

8. Solana R, Campos C, Pera A, Tarazona R. Shaping of NK cell subsets by aging. Curr Opin Immunol 2014;29:56–61.

9. Przemska-Kosicka A, Childs CE, Maidens C, et al. Age-related changes in the natural killer cell response to seasonal influenza vaccination are not influenced by a synbiotic: a randomised controlled trial. Front Immunol 2018;9:591.

10. Shaw AC, Goldstein DR, Montgomery RR. Age-dependent dysregulation of innate immunity. Nat Rev Immunol 2013;13:875–887.

11. Ginhoux F, Schultze JL, Murray PJ, Ochando J, Biswas SK. New insights into the multidimensional concept of macrophage ontogeny, activation and function. Nat Immunol 2016;17:34–40.

12. Hearps AC, Martin GE, Angelovich TA, et al. Aging is associated with chronic innate immune activation and dysregulation of monocyte phenotype and function. Aging Cell 2012;11:867–875.

13. Gupta S. Role of dendritic cells in innate and adaptive immune response in human aging. Exp Gerontol 2014;54:47–52.

14. Gardner JK, Cornwall SMJ, Musk AW, et al. Elderly dendritic cells respond to LPS/IFN-γ and CD40L stimulation despite incomplete maturation. PLoS One 2018;13:e0195313.

15. Brien JD, Uhrlaub JL, Hirsch A, Wiley CA, Nikolich-Zugich J. Key role of T cell defects in age-related vulnerability to West Nile virus. J Exp Med 2009;206:2735–2745.

16. Cicin-Sain L, Smyk-Pearson S, Currier N, et al. Loss of naive T cells and repertoire constriction predict poor response to vaccination in old primates. J Immunol 2010;184:6739–6745.

17. Uciechowski P, Kahmann L, Plümäkers B, et al. TH1 and TH2 cell polarization increases with aging and is modulated by zinc supplementation. Exp Gerontol 2008;43:493–498.

18. van Bruggen N, Ouyang W. Th17 cells at the crossroads of autoimmunity, inflammation, and atherosclerosis. Immunity 2014;40:10–12.

19. Schmitt V, Rink L, Uciechowski P. The Th17/Treg balance is disturbed during aging. Exp Gerontol 2013;48:1379–1386.

20. Palmer DB. The effect of age on thymic function. Front Immunol 2013;4:316.

21. Heldal K, Leivestad T, Hartmann A, Svendsen MV, Lien BH, Midtvedt K. Kidney transplantation in the elderly--the Norwegian experience. Nephrol Dial Transplant 2008;23:1026–1031.

22. Collins AJ, Foley RN, Gilbertson DT, Chen SC. The state of chronic kidney disease, ESRD, and morbidity and mortality in the first year of dialysis. Clin J Am Soc Nephrol 2009;4:Suppl 1. S5–S11.

23. Kuypers DR. Immunotherapy in elderly transplant recipients: a guide to clinically significant drug interactions. Drugs Aging 2009;26:715–737.

24. Lim JH, Lee GY, Jeon Y, et al. Elderly kidney transplant recipients have favorable outcomes but increased infection-related mortality. Kidney Res Clin Pract 2022;41:372–383.

25. Tullius SG, Reutzel-Selke A, Egermann F, et al. Contribution of prolonged ischemia and donor age to chronic renal allograft dysfunction. J Am Soc Nephrol 2000;11:1317–1324.

26. Basar H, Soran A, Shapiro R, et al. Renal transplantation in recipients over the age of 60: the impact of donor age. Transplantation 1999;67:1191–1193.

27. Terasaki PI, Gjertson DW, Cecka JM, Takemoto S, Cho YW. Significance of the donor age effect on kidney transplants. Clin Transplant 1997;11(5 Pt 1):366–372.

28. Remuzzi G, Cravedi P, Perna A, et al. Long-term outcome of renal transplantation from older donors. N Engl J Med 2006;354:343–352.

29. Liu Z, Liang Q, Ren Y, et al. Immunosenescence: molecular mechanisms and diseases. Signal Transduct Target Ther 2023;8:200.

30. Kauffman HM, McBride MA, Cors CS, Roza AM, Wynn JJ. Early mortality rates in older kidney recipients with comorbid risk factors. Transplantation 2007;83:404–410.

31. Chanan EL, Wagener G, Whitlock EL, et al. Perioperative considerations in older kidney and liver transplant recipients: a review. Transplantation 2024;Apr. 1. [Epub]. 10.1097/TP.0000000000005000.

32. Krenzien F, ElKhal A, Quante M, et al. A rationale for age-adapted immunosuppression in organ transplantation. Transplantation 2015;99:2258–2268.

33. Patel SJ, Knight RJ, Suki WN, et al. Rabbit antithymocyte induction and dosing in deceased donor renal transplant recipients over 60 yr of age. Clin Transplant 2011;25:E250–E256.

34. Lee JY, Kim SH, Park YH, et al. Antithymocyte globulin versus basiliximab induction for kidney transplantation in elderly patients: matched analysis within the Korean multicentric registry. Kidney Res Clin Pract 2022;41:623–634.

35. Robertsen I, Åsberg A, Ingerø AO, et al. Use of generic tacrolimus in elderly renal transplant recipients: precaution is needed. Transplantation 2015;99:528–532.

36. Tornatore KM, Logue G, Venuto RC, Davis PJ. Cortisol pharmacodynamics after methylprednisolone administration in young and elderly males. J Clin Pharmacol 1997;37:304–311.

37. Stuck AE, Frey BM, Frey FJ. Kinetics of prednisolone and endogenous cortisol suppression in the elderly. Clin Pharmacol Ther 1988;43:354–362.

38. Kim Y, Kang E, Chae DW, et al. Insufficient early renal recovery and progression to subsequent chronic kidney disease in living kidney donors. Korean J Intern Med 2022;37:1021–1030.

39. Budde K, Matz M, Dürr M, Glander P. Biomarkers of over-immunosuppression. Clin Pharmacol Ther 2011;90:316–322.

40. Steinebrunner N, Sandig C, Sommerer C, et al. Pharmacodynamic monitoring of nuclear factor of activated T cell-regulated gene expression in liver allograft recipients on immunosuppressive therapy with calcineurin inhibitors in the course of time and correlation with acute rejection episodes--a prospective study. Ann Transplant 2014;19:32–40.

41. Ducloux D, Bamoulid J, Courivaud C, et al. Thymic function, anti-thymocytes globulins, and cancer after renal transplantation. Transpl Immunol 2011;25:56–60.

42. Hricik DE, Nickerson P, Formica RN, et al. Multicenter validation of urinary CXCL9 as a risk-stratifying biomarker for kidney transplant injury. Am J Transplant 2013;13:2634–2644.

43. Jackson JA, Kim EJ, Begley B, et al. Urinary chemokines CXCL9 and CXCL10 are noninvasive markers of renal allograft rejection and BK viral infection. Am J Transplant 2011;11:2228–2234.

44. Schulz-Juergensen S, Burdelski MM, Oellerich M, Brandhorst G. Intracellular ATP production in CD4+ T cells as a predictor for infection and allograft rejection in trough-level guided pediatric liver transplant recipients under calcineurin-inhibitor therapy. Ther Drug Monit 2012;34:4–10.

45. Jun J, Park K, Lee HS, et al. Clinical relevance of postoperative proteinuria for prediction of early renal outcomes after kidney transplantation. Kidney Res Clin Pract 2022;41:707–716.

46. Kim J, Song SH, Oh TR, et al. Prognostic role of the neutrophil-to-lymphocyte ratio in patients with chronic kidney disease. Korean J Intern Med 2023;38:725–733.